Proteoglycans and Metabolic Disorders

Research in the laboratory focuses on evaluating the impact of glycans, in particular proteoglycans and human milk oligosaccharides, on hyperlipidemia, diabetes and cardiovascular disease.

Cardiovascular diseases are primarily caused by complications of atherosclerosis, resulting in heart attack, chest pain (angina) and stroke. Atherosclerosis is a disease initiated by focal infiltration and retention of lipoproteins in the subendothelial matrix of arteries due to a combination of aggregation and interaction with proteoglycans produced by the arteries.

Risk factor for cardiovascular disease include blood lipid levels, physical inactivity, obesity, diabetes, tobacco use, bad diet, hypertension and a family history.

Despite significant therapeutic advances cardiovascular disease still today remains the number one cause of death. Obesity and diabetes have become a worldwide epidemic and are in part responsible for setting-back progress made on cardiovascular disease risk-factor prevention.

Using reverse genetics approaches we want to determine the in vivo impact of proteoglycans and human milk oligosaccharides on hyperlipidemia, atherosclerosis, diabetes and obesity. The lab is also exploiting the natural mammalian glycan repertoire for therapeutic and prognostic purposes to help reduce the burden of cardiovascular disease and its detrimental consequences.

Philip Gordts
University of California, San Diego, School of Medicine
9500 Gilman Drive #0687, Room 4133 BRF2
La Jolla, CA 92093-0687
Phone office: +1-858-246-0994
Phone lab: +1-858-822-1102
Email: pgordts@ucsd.edu